357 related articles for article (PubMed ID: 32246853)
1. Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
Savic S; Leeman L; El-Shanawany T; Ellis R; Gach JE; Marinho S; Wahie S; Sargur R; Bewley AP; Nakonechna A; Randall R; Fragkas N; Somenzi O; Marsland A
Clin Exp Dermatol; 2020 Dec; 45(8):1003-1010. PubMed ID: 32246853
[TBL] [Abstract][Full Text] [Related]
2. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
3. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
[TBL] [Abstract][Full Text] [Related]
4. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
[TBL] [Abstract][Full Text] [Related]
5. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420
[TBL] [Abstract][Full Text] [Related]
6. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
[TBL] [Abstract][Full Text] [Related]
7. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
[TBL] [Abstract][Full Text] [Related]
10. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience.
Gimenez-Arnau A; Bartra J; Ferrer M; Jauregui I; Borbujo J; Figueras I; Muñoz-Bellido FJ; Pedraz J; Serra-Baldrich E; Tejedor-Alonso MA; Velasco M; Terradas P; Labrador M
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):191-199. PubMed ID: 33349612
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
12. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.
Rossi O; Piccirillo A; Iemoli E; Patrizi A; Stingeni L; Calvieri S; Gola M; Dapavo P; Cristaudo A; Zichichi L; Losappio L; Saccheri F; Pastorello EA
World Allergy Organ J; 2020 Dec; 13(12):100470. PubMed ID: 33343800
[TBL] [Abstract][Full Text] [Related]
13. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).
Lacour JP; Khemis A; Giordano-Labadie F; Martin L; Staumont-Salle D; Hacard F; Tian H; McBride D; Hollis K; Hunter S; Martin L; Lamirand A; Le Guen S; Balp MM; Berard F
Eur J Dermatol; 2018 Dec; 28(6):795-802. PubMed ID: 30698148
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Maurer M; Weller K
Allergy; 2018 Mar; 73(3):576-584. PubMed ID: 29058822
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
16. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
18. The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea.
Ye YM; Koh YI; Choi JH; Kim MA; Park JW; Kim TB; Nam YH; Chang YS; Park HS
Korean J Intern Med; 2022 Sep; 37(5):1050-1060. PubMed ID: 36068718
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria.
Kanters TA; Thio HB; Hakkaart L
Br J Dermatol; 2018 Sep; 179(3):702-708. PubMed ID: 29476533
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
